A randomized trial of icatibant in ACE-inhibitor-induced angioedema.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Angioedema induced by treatment with angiotensin-converting-enzyme (ACE) inhibitors accounts for one third of angioedema cases in the emergency room; it is usually manifested in the upper airway and the head and neck region. There is no approved treatment for this potentially life-threatening condition.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): N. Engl. J. Med.

Title: The New England journal of medicine

ISSN (Electronic): 1533-4406

ISSN (Print): 0028-4793

Publication date (Electronic): Jan 29 2015

Volume: 372

Issue: 5

Affiliations

[1 ] From the Department of Otorhinolaryngology (M.B., U.S.), Münchner Studienzentrum (B.S.), and Institut für Medizinische Statistik und Epidemiologie (A.H., V.K.), Klinikum rechts der Isar, Technische Universität München, and the Department of Otorhinolaryngology, Grosshadern Medical Center of the University of Munich (K.S., M.H.), Munich, the Department of Otorhinolaryngology, Head and Neck Surgery, Ulm University Medical Center, Ulm ( J.G., N.R., J.V., T.K.H), and the Institute of Pharmacology and Clinical Pharmacology, University Hospital Düsseldorf, Düsseldorf (G.K.) - all in Germany.

Article

DOI: 10.1056/NEJMoa1312524

PubMed ID: 25629740

SO-VID: 4b65afee-7d72-4c71-b78f-0ade68f7ad37

History

Data availability:

Comments

Comment on this article

scite_

Cited by 56

See all cited by